Ding Dong is the Skinny Label (Effectively) Dead?
FDA Law Blog
SEPTEMBER 6, 2021
Teva case, that the statutory provisions governing patent infringement, specifically induced infringement, do not address carve-outs. Especially now with the utility of the use code minimized. The catch is, as we have learned from the GSK v. Teva decision changed everything. But what is a “true carve-out?”
52 
Let's personalize your content